Argatroban Injection, Solution
Product Images NDC 25021-414

6 FDA label images from Sagent Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Argatroban (NDC 25021-414). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structural Formula (Arg06 0002 01)

Structural Formula (Arg06 0002 01)
Chemical structure diagram of Argatroban, showing its molecular components and configuration as depicted in the image.*
FDA Label Image

Figure 1 (Arg06 0002 02)

Figure 1 (Arg06 0002 02)
A chart illustrating the relationship at steady state between Argatroban infusion dose (in mcg/kg/min) depicted on the x-axis and plasma Argatroban concentration (in mcg/mL) and anticoagulant effect measured as aPTT (seconds) on the y-axes. The graph shows increasing values for both plasma concentration and aPTT with higher infusion doses.*
FDA Label Image

Figure 2 (Arg06 0002 03)

Figure 2 (Arg06 0002 03)
A scatter plot titled 'INR Relationship of Argatroban Plus Warfarin Versus Warfarin Alone' comparing INR values for Warfarin alone (x-axis) and Warfarin plus Argatroban (y-axis). Data points from 24 subjects are shown with linear regression lines for two thrombolastin conditions (ISI = 0.88 and ISI = 1.78). The plot includes regression equations and an error confidence interval for predicted Warfarin INR values.*
FDA Label Image

Figure 3 (Arg06 0002 04)

Figure 3 (Arg06 0002 04)
A line graph titled 'Study 1' comparing the proportion of event-free participants over a 35-day study period between Argatroban and a historical control group. The x-axis denotes study days from 0 to 35; the y-axis shows the proportion event-free from 0.0 to 1.0. Two survival curves depict higher event-free proportion for Argatroban versus control, with a p value of 0.007 indicating statistical comparison.*
FDA Label Image

Figure 4 (Arg06 0002 05)

Figure 4 (Arg06 0002 05)
A survival curve chart showing the proportion of event-free subjects over a 35-day study period. It compares two groups: Argatroban (N=144) and Historical Control (N=46), with event-free proportions plotted against study days. The graph includes p value = 0.018 indicating statistical comparison.*
FDA Label Image

Package Label – Principal Display Panel – Vial Label (Arg06 0002 06)

Package Label – Principal Display Panel – Vial Label (Arg06 0002 06)
Label for Argatroban Injection, USP 50 mg per 50 mL (1 mg per mL) intravenous injection solution by Sagent Pharmaceuticals. The label includes dosage strength, volume, administration instructions, storage conditions, and manufacturing details. The label is primarily blue with white and green text.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.